Targeted nanoparticle systems are widely explored in cancer nanomedicine research because they may improve the interaction between nanocarriers and selected biological targets. One common targeting strategy is the attachment of ligand molecules to the surface of nanoparticles. Folic acid is often used as a model ligand because folate receptors are overexpressed in several cancer cell types, making folic acid-functionalized particles useful for receptor-mediated uptake studies and targeted delivery models.

Nanoparticle functionalization is a sensitive process. The final conjugated dispersion can be affected by nanoparticle surface chemistry, ligand concentration, activation chemistry, p H condition, mixing intensity, incubation time, temperature, purification method, and storage condition. When such workflows are performed manually, small procedural differences may influence conjugation efficiency, particle aggregation, and batch-to-batch reproducibility.

Protoly can help convert this ligand-functionalization workflow into a structured protocol, while NSL can support selected physical operations such as liquid dispensing, stirring, mild heating, waiting, camera-based visual documentation, illumination, optional sonication, and chamber environment recording. This creates a reproducible preparation framework where different conjugation variables can be planned and compared in a more systematic manner.

This protocol focuses on preparation of folic acid-conjugated nanoparticles as a cancer cell targeting model. It does not claim therapeutic action or confirmed cancer selectivity by itself. The prepared conjugated nanoparticle dispersion should be validated externally using appropriate analytical and biological methods, including conjugation confirmation, particle size measurement, zeta potential analysis, stability testing, cell uptake studies, receptor-blocking controls, and cytotoxicity assessment.

This protocol is important because it converts a ligand-functionalization workflow into a structured, reproducible, and automation-assisted preparation format. Folic acid-conjugated nanoparticles are widely used as model systems in cancer nanomedicine research because folate receptor-mediated uptake has been investigated in several cancer cell models. However, the preparation of these conjugates is affected by multiple experimental variables, including nanoparticle surface chemistry, ligand concentration, activation chemistry, mixing conditions, incubation time, temperature, stabilizer use, and purification method.

By organizing the workflow through Protoly, each preparation condition can be recorded, standardized, and compared more clearly. The NSL platform supports key physical handling steps that influence preparation consistency, such as reagent dispensing, controlled stirring, mild heating, incubation, chamber illumination, camera-based documentation, exhaust control, and optional sonication. These automation-assisted steps help reduce manual variation during liquid addition, mixing, and incubation, while clearly identifying unsupported procedures such as purification, spectroscopy, particle-size analysis, and biological testing as offline steps.

A major advantage of this protocol is its usefulness in targeted nanomedicine education and early-stage formulation planning. It allows users to understand how nanoparticles can be modified with a targeting ligand and how different conjugation conditions may influence dispersion stability and surface functionalization. The workflow can be adapted for different nanoparticle cores, including gold, silver, chitosan, iron oxide, polymeric, or fluorescent nanoparticles, provided their surface chemistry is compatible with folic acid attachment.

This protocol also highlights the boundary between automation-supported preparation and external validation. Visual observation using chamber illumination and camera support can document colour change, turbidity, sedimentation, aggregation, foam formation, or phase separation. However, these observations cannot confirm successful folic acid conjugation. Confirmation requires external analytical techniques such as UV-Visible spectroscopy, fluorescence analysis, FTIR, DLS, zeta potential measurement, or other suitable surface-characterization methods. Similarly, cancer-cell targeting cannot be claimed without biological validation, including receptor-positive and receptor-negative cell models, uptake studies, receptor-blocking experiments, cytotoxicity testing, and proper controls.

Therefore, the prepared dispersion should be considered a research prototype or targeting model, not a validated therapeutic material. In future, this protocol can be expanded by comparing ligand concentrations, nanoparticle cores, stabilizers, incubation times, and purification approaches. It may also support later studies involving cell uptake, cytotoxicity, and payload-loaded targeted delivery models.

This protocol presents a Protoly-managed and partially NSL-supported workflow for preparing folic acid-conjugated nanoparticles as a cancer cell targeting model. The NSL-supported part of the workflow includes reservoir dispensing, stirring, mild heating, waiting, illumination, camera documentation, exhaust operation, optional sonication, and environmental condition recording.

The main value of the protocol is that it converts a manually variable ligand-functionalization process into a more structured and documented preparation workflow. It is suitable for nanomedicine education, targeting-model development, formulation screening, and early-stage research planning. The prepared conjugated nanoparticles should be evaluated externally for conjugation confirmation, particle size, surface charge, stability, receptor-related uptake, cytotoxicity, and biological relevance before any advanced biomedical interpretation is made.